Get the Stockscreener App
0.4511
1.46%
-0.0067
After Hours:
.45
-0.0011
-0.24%
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Ulcerated Necrobiosis Lipoidica Market to Expand Significantly by 2034, States DelveInsight Reports | Processa Pharmaceuticals - Barchart
Processa Pharmaceuticals stock hits 52-week low at $0.46 - Investing.com
Processa Pharma Stock Price, Quotes and Forecasts - Benzinga
The Insider Secrets to Processa Pharmaceuticals: A Dark Horse in the Race - Elblog.pl
Hidden Gems: Why Insiders Are Banking on Processa Pharmaceuticals - Bit Perfect Solutions
Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
10 Cheapest Stocks Insiders Are Buying Recently - Insider Monkey
Processa Pharmaceuticals faces Nasdaq delisting risk over share price By Investing.com - Investing.com Nigeria
Processa Pharmaceuticals (NASDAQ:PCSA) Publishes Investor Presentation - Defense World
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - Investing.com
Processa Pharmaceuticals IncOn Feb 4, Received Nasdaq Notice For Bid Price Non-Compliance - Marketscreener.com
Processa Pharmaceuticals Inc (PCSA) Shares Soar Above 1-Year High - The News Heater
Processa Pharmaceuticals to Present at 2025 BIO CEO & Investor Conference - Nasdaq
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewswire
Processa Pharma's Cancer Pipeline Takes Center Stage at Elite BIO Investor Conference - StockTitan
Gastroparesis Market Expected to rise, 2034 | Vanda - openPR
Financial Analysis: Processa Pharmaceuticals Inc (PCSA)’s Ratios Unveil Key Insights - The Dwinnex
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 - MSN
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Processa Pharmaceuticals Raises $5M in Public Offering - TipRanks
Processa CEO Doubles Down: Purchases Shares at 30% Premium in $5M Strategic Raise - StockTitan
Processa Pharmaceuticals director David Young buys $99,288 in stock - Investing.com India
Processa Pharmaceuticals' chief business officer buys $34,691 in stock - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Processa Pharmaceuticals' chief business officer buys $34,691 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals director David Young buys $99,288 in stock By Investing.com - Investing.com South Africa
Processa Pharmaceuticals CEO George Ng buys shares worth $69,542 By Investing.com - Investing.com UK
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Ulcerated Necrobiosis Lipoidica Market to Reach New Heights - openPR
Processa Pharmaceuticals stock hits 52-week low at $0.65 By Investing.com - Investing.com Canada
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa CEO and Board Members Double Down: Major Insider Buying in Latest $5M Deal - StockTitan
Gastroparesis Drugs Market to Grow by USD 1.34 Billion (2025-2029), Driven by Rising Global Diabetes Burden, AI's Role in Market TransformationTechnavio - Yahoo Finance
PROCESSA PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K) -June 09, 2021 at 01:17 pm EDT - Marketscreener.com
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
Processa Pharmaceuticals stock hits 52-week low at $0.8 - MSN
Processa Pharmaceuticals stock hits 52-week low at $0.8 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 0.6% – Here’s Why - Defense World
Gastroparesis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and FDA Approvals | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda, Neurogastrx, Inc, PTC Thera - The Globe and Mail
Processa Pharmaceuticals stock hits 52-week low at $0.81 By Investing.com - Investing.com South Africa
Processa Pharmaceuticals stock hits 52-week low at $0.81 - Investing.com
Gastroparesis Treatment Market Future Business Opportunities - openPR
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):